Literature DB >> 15180528

Phosphoinositide 3-kinases as targets for therapeutic intervention.

Reinhard Wetzker1, Christian Rommel.   

Abstract

Phosphoinositide 3-kinases (PI3K) represent a family of intracellular signaling proteins, which control a variety of important cellular functions such as proliferation, apoptosis and migration. Recent findings suggest an involvement of PI3K in the pathogenesis of numerous diseases including cancer, heart failure and autoimmune/inflammatory disorders. This review summarizes the current knowledge of the emerging therapeutic value of PI3K as targets for the intervention of several pathological disorders and in particular focusing on oncogenesis. A brief introduction on the molecular and biochemical features of these signaling proteins will be followed by a depiction of signaling interactions of PI3K in a cellular context. PI3K dependent signaling involved in the control of cell growth, proliferation, survival and cytoskeletal remodeling and the link to cellular dysfunctions will be discussed. Further we will summarize the phenotypic consequences by genetic targeting PI3K signaling in mice. In its final part this review outlines challenges and activities considering PI3K as targets for therapeutic intervention and progress in the development of first generation small molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15180528     DOI: 10.2174/1381612043384402

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  16 in total

Review 1.  Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.

Authors:  Margrith E Mattmann; Sydney L Stoops; Craig W Lindsley
Journal:  Expert Opin Ther Pat       Date:  2011-06-02       Impact factor: 6.674

Review 2.  New players in TLR-mediated innate immunity: PI3K and small Rho GTPases.

Authors:  Monica Ruse; Ulla G Knaus
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  Chemical synthesis and molecular recognition of phosphatase-resistant analogues of phosphatidylinositol-3-phosphate.

Authors:  Yong Xu; Stephanie A Lee; Tatiana G Kutateladze; Diego Sbrissa; Assia Shisheva; Glenn D Prestwich
Journal:  J Am Chem Soc       Date:  2006-01-25       Impact factor: 15.419

4.  Akt1 is critical for acute inflammation and histamine-mediated vascular leakage.

Authors:  Annarita Di Lorenzo; Carlos Fernández-Hernando; Giuseppe Cirino; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-21       Impact factor: 11.205

Review 5.  PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.

Authors:  Ipsita Pal; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2012-09-17       Impact factor: 6.150

6.  Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2β) isoform contributes to neuroblastoma tumorigenesis.

Authors:  Angela Russo; Mustafa Nazir Okur; Maarten Bosland; John P O'Bryan
Journal:  Cancer Lett       Date:  2015-01-23       Impact factor: 8.679

7.  Myocardial ischemic post-conditioning attenuates ischemia reperfusion injury via PTEN/Akt signal pathway.

Authors:  Chun-Mei Li; Shu-Wen Shen; Tao Wang; Xing-Hua Zhang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

8.  Targeting PI3K in neuroblastoma.

Authors:  Volker Spitzenberg; Christian König; Susanne Ulm; Romina Marone; Luise Röpke; Jörg P Müller; Michael Grün; Reinhard Bauer; Ignacio Rubio; Matthias Paul Wymann; Astrid Voigt; Reinhard Wetzker
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-12       Impact factor: 4.553

9.  Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.

Authors:  Fumihiko Furuya; John A Hanover; Sheue-yann Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

Review 10.  PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury?

Authors:  M M Mocanu; D M Yellon
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.